We wish to inform to the Exchange that TRIDENT MEDIQUIP LIMITED (TML) (CIN: U33309GJ2019PLC110421), a subsidiary company has made Private Placement of equity shares to other shareholders. ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.6 pts more than Nifty Microcap 250 and 0.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Trident Lifeline Ltd informed BSE that its subsidiary, Trident Mediquip Limited (TML), first allotted equity shares to other shareholders via a private placement, which diluted Trident Lifeline's holding in TML to 57.10%. Following this, Trident Lifeline acquired an additional 2.67% equity stake in TML from existing shareholders, raising its holding to 59.77%. TML operates in the pharmaceuticals and chemicals industry, with a turnover of Rs. 21.29 crore in FY25 (Rs. 20.58 crore in FY24, Rs. 28.77 crore in FY23). The transaction is a related party deal (TML being a subsidiary), but has been carried out at arm's length, with certain promoter-group directors having an interest in the acquired entity.
Trident Lifeline has consolidated its majority control in subsidiary TML, reinforcing its position in the pharma/chemicals segment. The dilution from the private placement to other shareholders slightly reduced the holding before the top-up, but net effect is a stronger grip on the subsidiary — a marginally positive signal for long-term consolidation, though the small size and related-party nature of the deal limit its broader stock impact.